Arrowhead Pharmaceuticals, Inc. ARWR R2K

Healthcare · Biotechnology · United States

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Market & Price

Market Cap

$10.97B

Current Price

$77.91

High / Low (52W)

$79.69 / $14.71

Beta

1.29

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$4.37

Price to Book

17.84

P/S

17.64

EV/EBITDA

-53.74

Dividend Yield

Profitability & Returns

ROCE

11.84%

ROE

-42.37%

ROA

-7.22%

Profit Margin

-48.38%

Op Margin

EPS (Latest Qtr)

$-0.93

EPS (TTM)

$-2.27

Balance Sheet & Liquidity

Debt/Equity

2.31

Quick Ratio

6.09

Current Ratio

6.23

Debt

$1.38B

Total Assets

$1.39B

Current Assets

$950.64M

Working Capital

$755.15M

Ownership

Promoter Holding

3.76%

Chg in Prom Hold

FII / Inst Holding

88.56%

Chg in FII Hold

-0.09%

Financial Snapshot

Enterprise Value

$10.56B

Total Revenue (TTM)

$622.01M

EBITDA

$-196.53M

Free Cash Flow

$-46.12M

Operating Cash Flow

$-36.31M

Shares Outstanding

140.86M

Gross Margin

100.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

50.52%

Profit 5Y

33.02%

Revenue (YoY)

-86.40%

Earnings (YoY)

PROS

Compounding revenue at 50.5% over 5 years.
Profit CAGR of 33.0% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ARWR Arrowhead Pharmaceuticals, Inc. R2K	77.91	-	$10.97B	-	11.84%	-42.37%	50.52%	33.02%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Dec 2021	Mar 2022	Jun 2022	Dec 2022	Mar 2023	Jun 2023	Dec 2023	Mar 2024	Jun 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	3.51M	650.12K	727.38K	11.26M	34.66M	48.15M	42.70M	43.29M	29.45M	23.53M	27.38M	7.63M	21.30M	32.81M	45.89M	27.44M	151.81M	32.41M	62.55M	146.27M	15.82M	3.55M	0	0	-	542.71M	27.77M	256.47M	264.03M	73.74M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	161.51M	193.32M	212.37M	223.22M	215.00M
Operating Income	-15.99M	-25.23M	-19.34M	-21.26M	-19.34M	-21.80M	-14.90M	-6.13M	-5.71M	-10.25M	-13.81M	-15.03M	-15.92M	-11.17M	10.95M	22.01M	18.60M	9.64M	-4.85M	-22.24M	-15.95M	-50.12M	-24.05M	-28.23M	-31.87M	-63.32M	41.55M	-72.91M	-42.13M	48.16M	-102.70M	-136.54M	-126.19M	-176.14M	-	381.20M	-165.55M	44.11M	40.81M	-141.26M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	397.34M	-148.48M	64.20M	57.17M	-107.35M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21.64M	24.38M	21.69M	22.50M	23.85M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	369.62M	-179.09M	36.12M	28.27M	-137.56M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.75M	-437.00K	20.00M	29.00K	7.00K
Net Income	-15.94M	-24.75M	-19.26M	-20.82M	-19.42M	-22.22M	-12.09M	-6.04M	-5.52M	-10.73M	-13.20M	-14.88M	-15.61M	-	12.04M	23.90M	20.34M	-	-2.67M	-19.84M	-13.61M	-	-20.73M	-26.82M	-29.92M	-62.87M	44.37M	-72.05M	-41.33M	48.67M	-102.95M	-132.86M	-125.30M	-170.79M	-	370.44M	-175.24M	-23.75M	30.81M	-132.73M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-0.18	-0.18	-0.18	-0.12	0.13	0.24	0.21	0.12	-0.03	-0.20	-0.13	-0.48	-0.20	-0.26	-0.29	-0.60	0.41	-0.68	-0.39	0.45	-0.96	-1.24	-1.02	-1.38	-1.39	2.75	-1.26	-	0.22	-0.93
R&D Expense	7.49M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	137.00M	133.10M	-	-	177.20M	173.25M

Profit & Loss (Annual)

Figures in USD.

Metric	Sep 2005	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Revenue	-	-	-	-	-	-	-	-	31.41M	16.14M	168.80M	87.99M	-	243.23M	240.74M	3.55M	829.45M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	421.74M	445.74M	604.63M	731.10M
Operating Income	-	-5.83M	-9.83M	-21.09M	-24.59M	-53.28M	-95.97M	-81.74M	-37.00M	-55.94M	61.19M	-93.16M	-	-178.51M	-205.00M	-601.08M	98.35M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-162.29M	-175.67M	-561.51M	164.82M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	0	18.33M	32.35M	89.36M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-172.71M	-206.49M	-612.46M	51.53M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	3.79M	2.78M	-2.77M	21.42M
Net Income	-6.73M	-5.77M	-3.13M	-21.13M	-31.14M	-58.63M	-91.94M	-81.72M	-34.38M	-54.45M	67.97M	-84.55M	-	-176.06M	-205.28M	-599.49M	-1.63M
Diluted EPS	-	-0.90	-0.40	-	-	-	-	-	-0.47	-0.65	0.69	-0.84	-	-1.67	-1.92	-5.00	-0.01
R&D Expense	-	529.60K	3.28M	5.39M	8.71M	23.14M	47.27M	-	-	-	-	-	-	-	353.19M	505.87M	607.16M

Compounded Sales Growth

5 Years:	50.52%
1 Year:	-86.40%

Compounded Profit Growth

5 Years:	33.02%
1 Year:	-

Stock Price Performance

1 Year:	+384.82%
6 Months:	+66.51%
3 Months:	+23.14%
1 Month:	+10.46%

Balance Sheet (Annual)

Figures in USD.

Metric	Sep 2003	Sep 2004	Sep 2005	Sep 2006	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Assets	-	-	-	-	-	-	-	12.35M	15.89M	16.53M	37.33M	182.82M	132.27M	128.18M	104.02M	111.61M	349.85M	522.50M	-	691.94M	765.55M	1.14B	1.39B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	405.30M	416.47M	695.47M	950.64M
Cash & Equivalents	-	-	-	-	-	-	2.02M	6.85M	7.51M	3.38M	19.11M	132.51M	81.21M	85.37M	24.84M	30.13M	221.80M	143.58M	-	108.00M	110.89M	76.21M	88.71M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.41M	0	0	6.82M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	273.60M	478.39M	948.74M	881.88M
Current Liabilities	-	-	-	-	-	-	-	4.28M	2.58M	5.33M	8.73M	11.85M	15.90M	25.64M	18.70M	12.36M	97.07M	40.68M	-	138.85M	105.46M	103.17M	195.49M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	393.18M	214.88M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	81.58M	115.17M	510.55M	366.28M
Total Equity	1.42M	11.23M	28.03M	31.61M	26.46M	12.30M	-	9.05M	12.79M	10.01M	27.50M	166.54M	110.18M	95.58M	81.42M	95.80M	244.59M	461.78M	-	398.52M	271.34M	185.44M	466.05M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	105.96M	107.31M	124.38M	138.36M

Cash Flows (Annual)

Figures in USD.

Metric	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Operating Cash Flow	-	-	-	-	-	-64.43M	-23.94M	-47.22M	173.03M	-95.80M	-	-136.13M	-153.89M	-462.85M	179.55M
Investing Cash Flow	-	-	-	-	-	13.45M	-48.64M	-7.43M	-47.75M	-240.78M	-	-5.42M	-96.16M	-420.07M	-129.29M
Financing Cash Flow	-	-	-	-	-	55.13M	12.06M	59.95M	66.38M	257.95M	-	65.19M	253.05M	870.52M	74.01M
Capital Expenditure	-9.67K	-479.71K	-296.88K	-1.72M	-1.97M	-3.86M	-7.92M	-1.42M	-12.00M	-11.95M	-	-52.78M	-176.74M	-141.47M	-22.67M
Free Cash Flow	-	-	-	-	-	-68.29M	-31.86M	-48.64M	161.03M	-107.75M	-	-188.91M	-330.63M	-604.32M	156.89M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-76.36M	3.01M	-12.40M	124.26M

Ratios (Annual)

Figures in %.

Metric	Sep 2005	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-117.8%	-346.5%	36.3%	-105.9%	-	-73.4%	-85.2%	-16,927.1%	11.9%
Net Margin %	-	-	-	-	-	-	-	-	-109.5%	-337.3%	40.3%	-96.1%	-	-72.4%	-85.3%	-16,882.4%	-0.2%
ROE %	-24.0%	-63.8%	-24.5%	-211.0%	-113.3%	-35.2%	-83.4%	-85.5%	-42.2%	-56.8%	27.8%	-18.3%	-	-44.2%	-75.7%	-323.3%	-0.3%
ROCE %	-	-72.2%	-73.9%	-188.3%	-86.0%	-31.2%	-82.5%	-79.7%	-43.4%	-56.4%	24.2%	-19.3%	-	-32.3%	-31.1%	-58.0%	8.3%

Shareholding Pattern

Insiders

3.76%

Institutions

88.56%

Public Float

92.02%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	12.89%	18.16M	$1.41B
2	Avoro Capital Advisors LLC	7.60%	10.70M	$833.64M
3	FMR, LLC	5.16%	7.27M	$566.14M
4	Vanguard Portfolio Management LLC	5.07%	7.15M	$556.76M
5	State Street Corporation	4.61%	6.50M	$506.11M
6	Vanguard Capital Management LLC	4.28%	6.03M	$469.99M
7	Geode Capital Management, LLC	3.04%	4.28M	$333.36M
8	Fred Alger Management, LLC	2.37%	3.34M	$260.41M
9	Invesco Ltd.	2.33%	3.28M	$255.60M
10	Vestal Point Capital, LP	1.62%	2.27M	$177.25M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ARWR

No recent headlines available.

ARWR · Healthcare